MetrioPharm AG Investor Relations News
-
Investor Relations News Update
MetrioPharm in the media (ARD, RBB): "The necessity of therapeutics in the fight against the corona pandemic", "Possible use of MP1032 in acute illness of patients with Covid-19"
-
MetrioPharm Investor Relations News QIV 2020
Greetings by CEO Dr. Wolfgang Brysch: "Our lead compound MP1032 is a highly promising candidate for the treatment of Covid-19.", MetrioPharm in the Media
-
Investor Relations News Update
MetrioPharm announced that it is preparing a Phase II clinical trial for its lead compound MP1032 in the fight against COVID-19.
-
Investor Relations News Update
A Current Publication by Dr. Wolfgang Brysch on the Prevention and Treatment of Covid-19
-
Investor Relations News Update:
MetrioPharm Announces Publication of Successful MP1032 Preclinical Data in Covid-19
-
Investor Relations News QIII 2020:
A letter from Dr. Wolfgang Brysch, CEO of MetrioPharm AG
-
Investor Relations News QII 2020
Topics: 14th Annual General Meeting of MetrioPharm AG, Company Calendar
-
Investor Relations News QI 2020
Topics: Edison Report, Company Calendar
-
Investor Relations News
MetrioPharm’s work in times of Covid-19
-
Investor Relations News QIV 2019
Topics: Retrospect 2019, BIO-Europe, Jefferies London Healthcare Conference, Warburg Bank “Meet the future” Conference, Essay by CEO Dr. Wolfgang Brysch: "Who wants to live forever?" (Blog)